6 research outputs found

    Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

    Get PDF
    Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≄30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≄90 days, chronic dialysis for ≄90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

    International Environmental Agreements for biodiversity conservation : a game-theoretic analysis

    No full text
    This paper contributes to the emerging literature on International Environmental Agreements with an analysis of key characteristics for biodiversity conservation. We study three features that are specific to an international conservation agreement: the existence of a natural upper bound of conservation in each country, the importance of local benefits, and the subadditivity of the global conservation function. We consider asymmetries in benefits and costs of conservation and, separately, in the upper bound of conservation in each country, and we examine the impacts of these features on coalition stability and on the effectiveness of biodiversity agreements. Results show that subadditivity of the global conservation function can lead to larger stable coalitions. The inclusion of a transfer scheme that might be implemented through, e.g., international trade of biodiversity credits, can have an impact on coalition composition and can improve conservation outcomes and the size of stable coalitions in certain ranges of the parameter space

    International cooperation on biodiversity conservation when spatial structures matter

    No full text
    International cooperation on biodiversity conservation when spatial structures matter. Spatial Economic Analysis. This paper considers the stability of international environmental agreements (IEAs) for biodiversity conservation with an explicit spatial structure. It studies the impact of distance between countries on coalition stability. It analyses a circular spatial structure with different spatial patterns. Robust results are obtained for a wide range of cost-and-benefit parameters: stable coalitions have a maximum size of two members. The best global payoff is obtained when coalitions are composed of neighbouring countries with the smallest possible distance. A ‘remoteness effect’ is observed, i.e., some coalitions of two members are unstable when one of the signatory countries is far away from the other coalition member and from the singletons

    B. Sprachwissenschaft

    No full text
    corecore